Adalimumab vs. Conventional Immunosuppression for Corticosteroid-sparing for Uveitis

Recruiting

99 years or below

All

1 Location

Brief description of study

The ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial is a randomized, comparative effectiveness trial comparing adalimumab to conventional agent immunosuppression for patients with non-infectious, intermediate, posterior, and panuveitides. Scheie Eye Institute, the Department of Ophthalmology, University of Pennsylvania will not enroll any patients under 18 years of age.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: uveitis
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 832873

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Adalimumab vs. Conventional Immunosuppression for Corticosteroid-sparing for Uveitis (ADVISE) Trial

Brief description of study

Eligibility of study

Find a site

Interested in the study